Dr. Marcello Rotta
Claim this profileColorado Blood Cancer Institute
Studies Acute Myeloid Leukemia
Studies Acute Myelogenous Leukemia
7 reported clinical trials
23 drugs studied
Area of expertise
1Acute Myeloid Leukemia
KMT2A positive
NPM1 positive
FLT3 positive
2Acute Myelogenous Leukemia
KMT2A positive
NPM1 positive
FLT3 positive
Affiliated Hospitals
Clinical Trials Marcello Rotta is currently running
Ziftomenib Combinations
for Acute Myeloid Leukemia
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in patients who have AML with certain genetic mutations. Both newly diagnosed and relapsed refractory patients with AML will be assigned to different cohorts based on specific study criteria and physician discretion. The purpose of this study is to assess the safety, tolerability, and early signs of efficacy of ziftomenib in combination with SOC drugs to treat AML.
Recruiting1 award Phase 1
Reduced-Dose Cyclophosphamide
for Leukemia After Stem Cell Transplant
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?
Recruiting1 award Phase 2
More about Marcello Rotta
Clinical Trial Related2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Marcello Rotta has experience with
- Venetoclax
- Azacitidine
- Ziftomenib
- Daunorubicin
- Cytarabine
- Dexamethasone
Breakdown of trials Marcello Rotta has run
Acute Myeloid Leukemia
Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marcello Rotta specialize in?
Marcello Rotta focuses on Acute Myeloid Leukemia and Acute Myelogenous Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved KMT2A positive patients, or patients who are NPM1 positive.
Is Marcello Rotta currently recruiting for clinical trials?
Yes, Marcello Rotta is currently recruiting for 3 clinical trials in Denver Colorado. If you're interested in participating, you should apply.
Are there any treatments that Marcello Rotta has studied deeply?
Yes, Marcello Rotta has studied treatments such as Venetoclax, Azacitidine, Ziftomenib.
What is the best way to schedule an appointment with Marcello Rotta?
Apply for one of the trials that Marcello Rotta is conducting.
What is the office address of Marcello Rotta?
The office of Marcello Rotta is located at: Colorado Blood Cancer Institute, Denver, Colorado 80218 United States. This is the address for their practice at the Colorado Blood Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.